Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs72.6%; p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer.
📊
Key Findings & Data:The aimof this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based onneoadjuvant chemotherapy (NAC).Material and Methods: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed.Results: A total of 99 patients with a median age of 59.0 years (range, 22-87 years) were studied.
💡
Conclusion & Impact:Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs72.6%; p
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aimof this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based onneoadjuvant chemotherapy (NAC).Material and Methods: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed.Results: A total of 99 patients with a median age of 59.0 years (range, 22-87 years) were studied. The median follow-up time was 39±32.7months, 81 patients (81.8%) died and 18 patients (18.2%) were alive. The five-year survival rate was 27.6%. Of the patients, 37 (37.4%) wereunderwent surgery after NAC, 62 (62.3%) were primary. More patients with NAC died within 3 years compared with those without NAC (83.9%vs 56.0%) (p=0.015). Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs72.6%; p
🔖
Cite This Article
SALİHOĞLU, Y., SÖZEN, H., SAİP, P., TOPUZ, S., KABAN, A. (2022). In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery. Journal of the Turkish-German Gynecological Association, Cilt: 20 - Sayı: 1, 31–36. https://ajindex.com/articles/567442
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108
Seidman JD, Yemelyanova A, Cosin JA, Smith A, Kurman RJ. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer 2012; 22: 367-71
Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61: 183-203
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384: 1376-8. 5. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16(Suppl 8): 7-12
Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol 2011; 29: 3628-35
Morgan RJ Jr, Alvarez RD, Armstrong DK, Robert A, Chen L, Copeland L, et al. Ovarian Cancer, Version 2.2013. J Natl Compr Canc Netw 2013; 11: 1199-209
National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55: 4-14
NCCN. Practice guidelines in Oncology v.2.2010 Ovarian Fallopian Tube and Primary Peritoneal Carcinomas; 2010
Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, et al. Does neoadjuvant chemotherapy impair longterm survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol 2014; 132: 292-8
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener HC, Lopes T, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. J Clin Oncol 2013; 31: 5500
Da Costa Miranda V, De Souza Fêde ÂB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian